## Contents

### Highlights of This Issue 391

#### SPECIAL FEATURES

**CCR Translations**

- **393** Response to Combined Molecular Targeting: Defining the Role of P-STAT3
  Ann Marie Egloff and Jennifer R. Grandis  
  *See article p. 483*

**CCR New Strategies**

- **396** New Strategies in Acute Lymphoblastic Leukemia: Translating Advances in Genomics into Clinical Practice
  Charles G. Mullighan

**Molecular Pathways**

- **401** Tumor Suppressor CHK2: Regulator of DNA Damage Response and Mediator of Chromosomal Stability
  Ailine Stolz, Norman Ertych, and Holger Bastians

**Review**

- **406** Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
  Karel Eechoute, Alex Sparreboom, Herman Burger, Ryan M. Franke, Gaia Schiavon, Jaap Verweij, Walter J. Loos, Erik A.C. Wiemer, and Ron H.J. Mathijsen

### HUMAN CANCER BIOLOGY

- **416** Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis
  Moriko Ito, Louise Barys, Terence O’Reilly, Sophie Young, Bella Gorbacheva, John Monahan, Sabine Zumstein-Mecker, Peter F. Choong, Ian Dickinson, Philip Crowe, Christine Hemmings, Jayesh Desai, David M. Thomas, and Joanna Lisztwan

- **427** Expression and Functional Significance of HtrA1 Loss in Endometrial Cancer
  Sally A. Mullaney, Mehdil Moslemi-Kebria, Ramandee Rattan, Ashwani Khurana, Amy Clayton, Takayo Ota, Andrea Mariani, Karl C. Podratz, Jeremy Chien, and Viji Shridhar

- **437** Endogenous Versus Tumor-Specific Host Response to Breast Carcinoma: A Study of Stromal Response in Synchronous Breast Primaries and Biopsy Site Changes
  Julie M. Wu, Andrew H. Beck, Lisa L. Pate, Daniela Witten, Shirley X. Zhu, Kelli D. Montgomery, Kimberly H. Allison, Matt van de Rijn, and Robert B. West

### CANCER THERAPY: PRECLINICAL

- **447** Vandetanib Improves Anti-Tumor Effects of L19mTNFα in Xenograft Models of Esophageal Cancer
  Marika Crescenzi, Luca Persano, Giovanni Esposito, Elisabetta Zulato, Laura Borsi, Enrica Balza, Alberto Ruol, Ermanno Ancona, Stefano Indraccolo, and Alberto Amadori

- **459** Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis
  Hilary A. Kenny, Payton Leonardt, Andras Ladayni, S. Diane Yamada, Anthony Montag, Hae Kyung Im, Sujatha Jagadeeswaran, David E. Shaw, Andrew P. Mazar, and Ernst Lengyel
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>472</td>
<td>HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation</td>
<td>David Liska, Chin-Tung Chen, Thomas Bachleitner-Hofmann, James G. Christensen, and Martin R. Weiser</td>
</tr>
<tr>
<td>483</td>
<td>Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth</td>
<td>Nagathihalli S. Nagaraj, M. Kay Washington, and Nipun B. Merchant. <em>See commentary p. 393</em></td>
</tr>
<tr>
<td>494</td>
<td>Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma</td>
<td>Kathleen I. Pishas, Fares Al-Ejeh, Irene Zinonos, Raman Kumar, Andreas Evdokiiou, Michael P. Brown, David F. Callen, and Paul M. Neilsen</td>
</tr>
<tr>
<td>505</td>
<td>Notch Pathway Inhibition Significantly Reduces Rhabdomyosarcoma Invasiveness and Mobility <em>In Vitro</em></td>
<td>Josep Roma, Anna Masià, Jaume Reventós, Josep Sánchez de Toledo, and Soledad Gallego</td>
</tr>
<tr>
<td>514</td>
<td>Distinct Interactions Between c-Src and c-Met in Mediating Resistance to c-Src Inhibition in Head and Neck Cancer</td>
<td>Banibrata Sen, Shaohua Peng, Babita Saigal, Michelle D. Williams, and Faye M. Johnson</td>
</tr>
<tr>
<td>525</td>
<td>Forkhead Transcription Factor FOXO1 is a Direct Target of Progestin to Inhibit Endometrial Epithelial Cell Growth</td>
<td>Satoru Kyo, Junko Sakaguichi, Tohru Kiyono, Yutaka Shimizu, Yoshiko Maida, Yasunari Mizumoto, Noriko Mori, Mitsuhito Nakamura, Masahiro Takakura, Kiyohiko Miyake, Masaru Sakamoto, and Masaki Inoue</td>
</tr>
<tr>
<td>550</td>
<td>Longitudinal Investigation of Permeability and Distribution of Macromolecules in Mouse Malignant Transformation using PET</td>
<td>Cecile B. Rygh, Shengping Qin, Jai W. Seo, Lisa M. Mahakian, Hua Zhang, Roger Adamson, Jane Q. Chen, Alexander D. Borowsky, Robert D. Cardiff, Rolf K. Reed, Fitz-Roy E. Curry, and Katherine W. Ferrara</td>
</tr>
<tr>
<td>581</td>
<td>A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer</td>
<td>Martijn P. Lolkema, Hendrik-Tobias Arkenau, Kevin Harrington, Patricia Roxburgh, Rosemary Morrison, Victoria Roulstone, Katie Twigger, Matt Coffey, Karl Mettinger, George Gill, T.R. Jeffry Evans, and Johann S. de Bono</td>
</tr>
<tr>
<td>589</td>
<td>Phase 1 Study of Valproic Acid in Pediatric Patients with Refractory Solid or CNS Tumors: A Children's Oncology Group Report</td>
<td>Jack M. Su, Xiao-Nan Li, Patrick Thompson, Ching-Nan Ou, Ashish M. Ingle, Heidi Russell, Ching C. Lau, Peter C. Adamson, and Susan M. Blaney</td>
</tr>
</tbody>
</table>
Modulation of Genetic and Epigenetic Biomarkers of Colorectal Cancer in Humans by Black Raspberries: A Phase I Pilot Study
Li-Shu Wang, Mark Arnold, Yi-Wen Huang, Christine Sardo, Claire Seguin, Edward Martin, Tim H.-M. Huang, Ken Riedl, Steven Schwartz, Wendy Frankel, Dennis Pearl, Yiqing Xu, John Winston III, Guang-Yu Yang, and Gary Stoner

Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors
Rochelle Bagatell, Cynthia E. Herzog, Tanya M. Trippett, Joseph F. Grippo, Georgina Cirrincione-Dall, Elizabeth Fox, Margaret Macy, Jennifer Bish, Patricia Whitcomb, Alberta Aiken, Gerry Wright, Sergey Yurasov, Frank M. Balis, and Lia Gore

Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
Astrid A.M. van der Veldt, Karel Eechout, Hans Gelderblom, Jourik Gietema, Henk-Jan Guchelaar, Nielska P. van Erp, Alfons J.M. van den Eertwegh, John B. Haanen, Ron H.J. Mathijssen, and Judith A.M. Wessels

Correction: Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

Correction: In vitro and Clinical Studies of Gene Therapy with Recombinant Human Adenovirus-p53 Injection for Oral Leukoplakia

ABOUT THE COVER
Rapid restoration of tumor microvasculature and perfusion in esophageal cancer xenografts treated with a vascular disrupting agent. Kyse-30 tumors were analyzed two weeks after administration of one single dose of the immunolabeled L19mTNFa. Microvessels were stained by anti-CD31 (red), whereas perfusion was evaluated by injection of Dextran-FITC 70 kDa (green). Nuclei were stained by TOPRO-3 (blue). For further details, please see Crescenzi and coworkers on page 447 in this issue.